Coherus Oncology (CHRS) Share-based Compensation (QoQ) (2014 - 2026)
Coherus Oncology (CHRS) Share-based Compensation (QoQ) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Coherus Oncology | 194.37 Mn | 27.32 Mn | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16,935.71% |
| Dec 31, 2025 | -26.32% |
| Sep 30, 2025 | -55.81% |
| Jun 30, 2025 | -82.30% |
| Mar 31, 2025 | 122.95% |
| Dec 31, 2024 | -115.42% |
| Sep 30, 2024 | 1,617.00% |
| Jun 30, 2024 | 1.52% |
| Mar 31, 2024 | 7.95% |
| Dec 31, 2023 | -96.33% |
| Sep 30, 2023 | -1.23% |
| Jun 30, 2023 | 7,592.37% |
| Mar 31, 2023 | 100.37% |
| Dec 31, 2022 | -781.75% |
| Sep 30, 2022 | 13.05% |
| Jun 30, 2022 | 72.16% |
| Mar 31, 2022 | -75.72% |
| Dec 31, 2021 | 4,441.91% |
| Sep 30, 2021 | -94.10% |
| Jun 30, 2021 | 410.50% |